Coherus Oncology, Inc. (CHRS) Form 8-K — Jun 15, 2026

$CHRSForm 8-KItems 4.01, 9.01Filed Jun 15, 2026, 4:40 PM ET0001104659-26-074090Original filing

Coherus Oncology dismissed Ernst & Young LLP as its independent registered public accounting firm effective June 12, 2026. The company simultaneously selected PricewaterhouseCoopers LLP to serve as its new auditor for the fiscal year ending December 31, 2026. The company confirmed there were no disagreements with EY regarding accounting principles, financial statement disclosure, or auditing scope during the fiscal years 2024 and 2025. Additionally, there were no reportable events other than a previously disclosed material weakness related to inventory account reconciliations.

Price after filing

1 day: +1.5%7 days: +8.8%30 days: +8.1%

Close on the filing date to close N calendar days later (from $1.36). Historical, not a forecast.

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.